Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019

Molecular Psychiatry volume 28, pages 5319–5327 (2023)Cite this article

Subjects

Abstract

Schizophrenia substantially contributes to the burden of mental disorders. Schizophrenia’s burden and epidemiological estimates in some countries have been published, but updated estimates of prevalence, incidence, and schizophrenia-related disability at the global level are lacking. Here, we present the data from and critically discuss the Global Burden of Diseases, Injuries, and Risk Factors Study data, focusing on temporal changes in schizophrenia’s prevalence, incidence, and disability-adjusted life years (DALYs) globally. From 1990 to 2019, schizophrenia raw prevalence (14.2 to 23.6 million), incidence (941,000 to 1.3 million), and DALYs (9.1 to 15.1 million) increased by over 65%, 37%, and 65% respectively, while age-standardized estimates remained stable globally. In countries with high socio-demographic index (SDI), both prevalence and DALYs increased, while in those with low SDI, the age-standardized incidence decreased and DALYs remained stable. The male/female ratio of burden of schizophrenia has remained stable in the overall population over the past 30 years (i.e., M/F = 1.1), yet decreasing from younger to older age groups (raw prevalence in females higher than males after age 65, with males having earlier age of onset, and females longer life expectancy). Results of this work suggest that schizophrenia’s raw prevalence, incidence, and burden have been increasing since 1990. Age-adjusted estimates did not reduce. Schizophrenia detection in low SDI countries is suboptimal, and its prevention/treatment in high SDI countries should be improved, considering its increasing prevalence. Schizophrenia sex ratio inverts throughout the lifespan, suggesting different age of onset and survival by sex. However, prevalence and burden estimates for schizophrenia are probably underestimated. GBD does not account for mortality from schizophrenia (and other mental disorders, apart from anorexia nervosa).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Global age-standardized incidence, prevalence, and burden of schizophrenia.
Fig. 2: Global trends over time of prevalence of schizophrenia, and male-to-female ratio.
Fig. 3: Global age distribution of prevalence of schizophrenia, and male-to-female ratio.

Similar content being viewed by others

Data availability

Data are publicly available at the Institute for Health Metrics and Evaluation (IHME) website (http://www.ghdx.healthdata.org/gbd-results-tool).

References

  1. Correll CU. Pharmacotherapy of schizophrenia | Pharmakotherapie der Schizophrenie. Nervenarzt. 2020;91:34–42.

    Article  CAS  PubMed  Google Scholar 

  2. Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: A large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16:163–80.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Firth J, Solmi M, Wootton RE, Vancampfort D, Schuch FB, Hoare E, et al. A meta-review of “lifestyle psychiatry”: the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. World Psychiatry. 2020;19:360–80.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: A systematic review and meta-analysis. World Psychiatry. 2015;14:339–47.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: A systematic review and large scale meta-analysis. World Psychiatry. 2016;15:166–74.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Solmi M, Firth J, Miola A, Fornaro M, Frison E, Fusar-Poli P, et al. Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people. Lancet Psychiatry. 2020;7:52–63.

    Article  PubMed  Google Scholar 

  7. Solmi M, Fiedorowicz J, Poddighe L, Delogu M, Miola A, Høye A, et al. Disparities in Screening and Treatment of Cardiovascular Diseases in Patients With Mental Disorders Across the World: Systematic Review and Meta-Analysis of 47 Observational Studies. Am J Psychiatry. 2021;178:793–803.

    Article  PubMed  Google Scholar 

  8. Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21:248–71.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–22.

    Article  Google Scholar 

  10. GBD Collaborators Mental Disorders. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9:137–50.

    Article  Google Scholar 

  11. He H, Liu Q, Li N, Guo L, Gao F, Bai L, et al. Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017. Epidemiol Psychiatr Sci. 2020;29:e91–e91.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophr Bull. 2018;44:1195–203.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013;382:1575–86.

    Article  PubMed  Google Scholar 

  14. Grisales-Romero H, González D, Porras S. Años de vida saludable perdidos a causa de trastornos mentales y enfermedades del sistema nervioso de la población de Medellín, 2006-2012. Rev Colomb Psiquiatr. 2020;49:29–38.

    Article  Google Scholar 

  15. Baxter AJ, Charlson FJ, Cheng HG, Shidhaye R, Ferrari AJ, Whiteford HA. Prevalence of mental, neurological, and substance use disorders in China and India: a systematic analysis. Lancet Psychiatry. 2016;3:832–41.

    Article  PubMed  Google Scholar 

  16. Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010. PLoS One. 2015;10:e0116820–e0116820.

    Article  PubMed  PubMed Central  Google Scholar 

  17. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality. Epidemiol Rev. 2008;30:67–76.

    Article  PubMed  Google Scholar 

  18. Jaeschke K, Hanna F, Ali S, Chowdhary N, Dua T, Charlson F. Global estimates of service coverage for severe mental disorders: findings from the WHO Mental Health Atlas 2017. Glob Ment Heal. 2021;8:e27.

    Article  Google Scholar 

  19. Ayano G, Demelash S, yohannes Z, Haile K, Tulu M, Assefa D, et al. Misdiagnosis, detection rate, and associated factors of severe psychiatric disorders in specialized psychiatry centers in Ethiopia. Ann Gen Psychiatry. 2021;20:10.

    Article  PubMed  PubMed Central  Google Scholar 

  20. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th edn. Washington, D.C.: American Psychiatric Publishing, 2013.

  21. Association AP. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th edn. 2000.

  22. Tandon R, Gaebel W, Barch DM, Bustillo J, Gur RE, Heckers S, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res. 2013;150:3–10.

    Article  PubMed  Google Scholar 

  23. Tandon R. The Nosology of Schizophrenia: Toward DSM-5 and ICD-11. Psychiatr Clin. 2012;35:557–69.

    Google Scholar 

  24. Substance Abuse and Mental Health Services Administration. Impact of the DSM-IV to DSM-5 Changes on the National Survey on Drug Use and Health [Internet]. 22. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2016.

    Google Scholar 

  25. Tandon R, Bruijnzeel D, Rankupalli B. Does change in definition of psychotic symptoms in diagnosis of schizophrenia in DSM-5 affect caseness? Asian J Psychiatr. 2013;6:330–2.

    Article  PubMed  Google Scholar 

  26. Fusar-Poli P, Correll C, Arango C, Berk M, Patel V, Ioannidis J. Preventive psychiatry: a blueprint for improving the mental health of young people. World Psychiatry. 2021;20:200–21.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Radua J, Ramella-Cravaro V, Ioannidis JPA, Reichenberg A, Phiphopthatsanee N, Amir T, et al. What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry. 2018;17:49–66.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Belbasis L, Köhler CA, Stefanis N, Stubbs B, van Os J, Vieta E, et al. Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: an umbrella review of meta-analyses. Acta Psychiatr Scand. 2018;137:88–97.

    Article  CAS  PubMed  Google Scholar 

  29. Arango C, Dragioti E, Solmi M, Cortese S, Domschke K, Murray RM, et al. Risk and protective factors for mental disorders beyond genetics: an evidence-based atlas. World Psychiatry. 2021;20:417–36.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Davies C, Segre G, Estradé A, Radua J, De Micheli A, Provenzani U, et al. Prenatal and perinatal risk and protective factors for psychosis: a systematic review and meta-analysis. Lancet Psychiatry. 2020;7:399–410.

    Article  PubMed  Google Scholar 

  31. Oliver D, Reilly TJ, Baccaredda Boy O, Petros N, Davies C, Borgwardt S, et al. What Causes the Onset of Psychosis in Individuals at Clinical High Risk? A Meta-analysis of Risk and Protective Factors. Schizophr Bull. 2020;46:110–20.

    Article  PubMed  Google Scholar 

  32. Fusar-Poli P, Radua J. Ten simple rules for conducting umbrella reviews. Evid Based Ment Health. 2018;21:95–100.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Ioannidis JPA. Integration of evidence from multiple meta-analyses: A primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ 2009;181:488–93.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Solmi M, Dragioti E, Croatto G, Radua J, Borgwardt S, Carvalho AF, et al. Risk and protective factors for cannabis, cocaine, and opioid use disorders: An umbrella review of meta-analyses of observational studies. Neurosci Biobehav Rev. 2021;126:243–51.

    Article  CAS  PubMed  Google Scholar 

  35. Fusar-Poli P, Solmi M, Brondino N, Davies C, Chae C, Politi P, et al. Transdiagnostic psychiatry: a systematic review. World Psychiatry. 2019;18:192–207.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Dragioti E, Radua J, Solmi M, Arango C, Oliver D, Cortese S, et al. Global population attributable fraction of potentially modifiable risk factors for mental disorders: a meta-umbrella systematic review. Mol Psychiatry. 2022;27:3510–9.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Taipale H, Solmi M, Lähteenvuo M, Tanskanen A, Correll CU, Tiihonen J. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. Lancet Psychiatry. 2021;8:883–91.

    Article  PubMed  Google Scholar 

  38. Solmi M, Tiihonen J, Lähteenvuo M, Tanskanen A, Correll C, Taipale H. Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study. Schizophir Bull. 2021. 21 July 2021. https://doi.org/10.1093/SCHBUL/SBAB087.

  39. Charlson, F. J., Baxter, A. J., Dua, T., Degenhardt, L., Whiteford, H. A., & Vos, T. Excess mortality from mental, neurological and substance use disorders in the Global Burden of Disease Study 2010. Epidemiology and psychiatric sciences, 2015;24:121–140.

  40. Solmi M, Radua J, Olivola M, Croce E, Soardo L, Salazar de Pablo G, et al. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Mol Psychiatry. 2021;27:281–95.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: Systematic review and meta-analysis. Drug Alcohol Depend. 2018;191:234–58.

    Article  PubMed  Google Scholar 

  42. Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. “Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis”: Correction. Lancet Psychiatry. 2017;4:e19–e19.

    Article  Google Scholar 

  43. Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013;170:324–33.

  44. Lawrence D, Hancock KJ, Kisely S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: Retrospective analysis of population based registers. BMJ. 2013;346:f2539.

  45. Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, et al. Schizophrenia. Nat Rev Dis Prim. 2015;1:1–23.

    Google Scholar 

  46. De Hert M, Schreurs V, Vancampfort D, VAN Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8:15–22.

  47. Vancampfort D, Firth J, Schuch FB, Rosenbaum S, Mugisha J, Hallgren M, et al. Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. World Psychiatry. 2017;16:308–15.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Ottawa, Ottawa, ON, Canada

    Marco Solmi, Lauri Tuominen & Aroldo Dargél

  2. On Track: The Champlain First Episode Psychosis Program, Department of Mental Health, The Ottawa Hospital, Ottawa, ON, Canada

    Marco Solmi & Aroldo Dargél

  3. Ottawa Hospital Research Institute (OHRI) Clinical Epidemiology Program, University of Ottawa, Ottawa, ON, Canada

    Marco Solmi & Aroldo Dargél

  4. School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada

    Marco Solmi

  5. Centre for Innovation in Mental Health (CIMH), School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK

    Marco Solmi & Samuele Cortese

  6. Department of Child and Adolescent Psychiatry, Charité-Universitätsmedizin Berlin, Berlin, Germany

    Marco Solmi & Christoph U. Correll

  7. Department of Primary Education, Evidence Synthesis Methods Team, University of Ioannina, Ioannina, Greece

    Georgios Seitidis & Dimitris Mavridis

  8. Faculté de Médecine, Paris Descartes University, Sorbonne Paris Cité, Paris, France

    Dimitris Mavridis

  9. Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, USA

    Christoph U. Correll

  10. Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA

    Christoph U. Correll

  11. Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA

    Christoph U. Correll

  12. Pain and Rehabilitation Centre, and Department of Health, Medicine and Caring Sciences, Linkoping University, SE-581 85, Linkoping, Sweden

    Elena Dragioti

  13. Department of psychoeducation and psychology, University of Quebec in Outaouais, Gatineau, Canada

    Synthia Guimond

  14. Department of psychiatry, University of Ottawa, The Royal’s Institute of Mental Health Research, Ottawa, Canada

    Synthia Guimond & Lauri Tuominen

  15. Ottawa Hospital Research Institute (OHRI) Neuroscience Program, University of Ottawa, Ottawa, ON, Canada

    Aroldo Dargél

  16. IMPACT (Innovation in Mental and Physical Health and Clinical Treatment) Strategic Research Centre, School of Medicine, Barwon Health, Deakin University, Geelong, VIC, Australia

    Andre F. Carvalho

  17. Section of Psychiatry, Department of Neuroscience, Reproductive Science, and Dentistry, Federico II University of Naples, Naples, Italy

    Michele Fornaro

  18. University of Electronic Science and Technology of China, Chengdu, 611731, China

    Michael Maes

  19. Department of Psychiatry, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, the Thai Red Cross Society, Bangkok, Thailand

    Michael Maes

  20. Department of Psychiatry, and Research Institute, Medical University of Plovdiv, Plovdiv, Bulgaria

    Michael Maes

  21. Department of Mental Health, ASL Salerno, Salerno, Italy

    Francesco Monaco

  22. European Biomedical Research Institute of Salerno (EBRIS), Salerno, Italy

    Francesco Monaco

  23. Yonsei University College of Medicine, Seoul, Republic of Korea

    Minjin Song

  24. Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea

    Jae Il Shin

  25. Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK

    Samuele Cortese

  26. Hassenfeld Children’s Hospital at NYU Langone, New York University Child Study Center, New York City, USA

    Samuele Cortese

  27. Solent NHS Trust, Southampton, UK

    Samuele Cortese

Authors
  1. Marco Solmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Georgios Seitidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dimitris Mavridis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christoph U. Correll
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elena Dragioti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Synthia Guimond
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lauri Tuominen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Aroldo Dargél
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Andre F. Carvalho
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Michele Fornaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Michael Maes
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Francesco Monaco
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Minjin Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Jae Il Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Samuele Cortese
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed and approved the study’s protocol. MS created the first draft of the manuscript. MS, DY, and SL analysed data. MS, JS, MF, and SC provided overall guidance. Finally, all authors read, edited, and approved the final version of the manuscript.

Corresponding authors

Correspondence to Marco Solmi or Jae Il Shin.

Ethics declarations

Competing interests

MS received honoraria/has been consultant for AbbVie, Angelini, Lundbeck, Otsuka. CUC has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Novo Nordisk,Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma and Quantic. MF received consulting fees & fees for non-CME/CE services from: Angelini, AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, Eli Lilly, GlaxoSmithKline, Innova Pharma, Lundbeck, Pfizer, Sanofi, Servier. All outside of the present work. SCo has received honoraria from the following non-profit associations: British Association for Psychopharmacology (BAP), Association for Child and Adolescent mental health (ACAMH), and Canadian ADHD Alliance Resource (CADDRA). SG received honoraria/has been consultant for Boehringer Ingelheim. Other authors have no conflict of interest o declare.

Ethical approval

We followed the standard procedure recommended registering additional publications from the GBD 2019 project after the publication of the capstone paper [9]. The Institutional Review Board approved our study at Yonsei University Health System for data use.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Solmi, M., Seitidis, G., Mavridis, D. et al. Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Mol Psychiatry 28, 5319–5327 (2023). https://doi.org/10.1038/s41380-023-02138-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41380-023-02138-4

This article is cited by

Search

Advanced search

Quick links